The above results implied that mTOR could be involved in regulating the immune infiltrates in ccRCC patients, which was consistent with previous reports (Diaz-Montero, Rini & Finke, 2020; Zhang et al., 2019). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.